Alpha 2.0
Login Register
» Authors » Inder Chaudhary

Inder Chaudhary

Explore the profile of Inder Chaudhary including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 393
Followers 0
Related Specialties
Chemistry
Biochemistry
Oncology
Top 10 Co-Authors
Judy Lucas
Semiramis Ayral-Kaloustian
Zecheng Chen
Tarek S Mansour
Ker Yu
Efren Delos Santos
Osvaldo dos Santos
Robert Mallon
Aranapakam M Venkatesan
Larry Feldberg
Published In
J Med Chem
Bioorg Med Chem Lett
Cancer Biol Ther
Cancer Chemother Pharmacol
J Pharmacol Exp Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder
Adjei A, Chaudhary I, Kollins S, Padilla A
Paediatr Drugs . 2020 Aug; 22(5):561-570. PMID: 32776159
Objective: This was a single-dose, one-period, multicenter, pharmacokinetic (PK) study to evaluate the PK of methylphenidate (MPH) hydrochloride multilayer extended-release capsules (MPH-MLR) in preschool children aged 4 to < 6 ...
2.
Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical...
Wang X, Zhan Y, Zhao L, Alvarez J, Chaudhary I, Zhou B, et al.
J Pharmacol Exp Ther . 2011 Aug; 339(2):421-9. PMID: 21835932
The mammalian target of rapamycin (mTOR) has proven to be a valid therapeutic target in a number of human cancers, and it is a candidate for clinical trials in human...
3.
Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor
Mallon R, Feldberg L, Lucas J, Chaudhary I, Dehnhardt C, Santos E, et al.
Clin Cancer Res . 2011 Feb; 17(10):3193-203. PMID: 21325073
Purpose: The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual phosphoinositide 3-kinase (PI3K)/mTOR inhibitor. Experimental Design: In vitro class 1 PI3K...
4.
Application of quantitative NMR in pharmacological evaluation of biologically generated metabolites: implications in drug discovery
Mutlib A, Espina R, Vishwanathan K, Babalola K, Chen Z, Dehnhardt C, et al.
Drug Metab Dispos . 2010 Oct; 39(1):106-16. PMID: 20952552
It is important to gain an understanding of the pharmacological activities of metabolite(s) of compounds in development, especially if they are found in systemic circulation in humans. Pharmacological evaluation of...
5.
PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
Venkatesan A, Chen Z, dos Santos O, Dehnhardt C, Santos E, Ayral-Kaloustian S, et al.
Bioorg Med Chem Lett . 2010 Aug; 20(19):5869-73. PMID: 20797855
A series of mono-morpholino 1,3,5-triazine derivatives (8a-8q) bearing a 3-oxa-8-azabicyclo[3.2.1]octane were prepared and evaluated for PI3-kinase/mTOR activity. Replacement of one of the bis-morpholines in lead compound 1 (PKI-587) with 3-oxa-8-azabicyclo[3.2.1]octane...
6.
Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors
Boschelli D, Wang D, Wang Y, Wu B, Honores E, Barrios Sosa A, et al.
Bioorg Med Chem Lett . 2010 Apr; 20(9):2924-7. PMID: 20363128
The 7-alkene-3-quinolinecarbonitrile 20, a potent inhibitor of Src enzymatic and cellular activity with IC(50) values of 2.1 and 58 nM, respectively, had comparable efficacy to bosutinib in a colon tumor...
7.
Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor
Venkatesan A, Dehnhardt C, Santos E, Chen Z, dos Santos O, Ayral-Kaloustian S, et al.
J Med Chem . 2010 Feb; 53(6):2636-45. PMID: 20166697
The PI3K/Akt signaling pathway is a key pathway in cell proliferation, growth, survival, protein synthesis, and glucose metabolism. It has been recognized recently that inhibiting this pathway might provide a...
8.
Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition
Dehnhardt C, Venkatesan A, Chen Z, Ayral-Kaloustian S, dos Santos O, Santos E, et al.
J Med Chem . 2009 Dec; 53(2):897-910. PMID: 20025292
We are introducing a novel series of 2,4-diaminoquinazolines as beta-catenin/Tcf4 inhibitors which were identified by ligand-based design. Here we elucidate the SAR of this series and explain how we were...
9.
Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402
Dehnhardt C, Venkatesan A, Santos E, Chen Z, Santos O, Ayral-Kaloustian S, et al.
J Med Chem . 2009 Dec; 53(2):798-810. PMID: 19968288
Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good...
10.
Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates
Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, et al.
J Med Chem . 2009 Nov; 53(1):452-9. PMID: 19928864
Hyperactivation of the PI3K/AKT/mTOR signaling pathway is common in cancer, and PI3K and mTOR act synergistically in promoting tumor growth, survival, and resistance to chemotherapy. Thus, combined targeting of PI3K...